{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T07:34:53Z","timestamp":1780472093801,"version":"3.54.1"},"reference-count":82,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2013,6,1]],"date-time":"2013-06-01T00:00:00Z","timestamp":1370044800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1016\/j.semarthrit.2012.10.006","type":"journal-article","created":{"date-parts":[[2013,1,18]],"date-time":"2013-01-18T19:01:10Z","timestamp":1358535670000},"page":"597-618","source":"Crossref","is-referenced-by-count":38,"title":["The use of biologic response modifiers in polyarticular-course juvenile idiopathic arthritis: A systematic review"],"prefix":"10.1016","volume":"42","author":[{"given":"Wendy J.","family":"Ungar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vania","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather F.","family":"Burnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian M.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald M.","family":"Laxer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9563","key":"10.1016\/j.semarthrit.2012.10.006_bib1","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/S0140-6736(07)60363-8","article-title":"Juvenile idiopathic arthritis","volume":"369","author":"Ravelli","year":"2007","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.10.006_bib2","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1097\/00002281-200109000-00009","article-title":"Juvenile idiopathic arthritis","volume":"13","author":"Kulas","year":"2001","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib3","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.autrev.2005.09.011","article-title":"Juvenile idiopathic arthritis","volume":"5","author":"Borchers","year":"2006","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib4","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1345\/aph.10123","article-title":"Etanercept in juvenile rheumatoid arthritis","volume":"35","author":"Johnson","year":"2001","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.10.006_bib5","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/adc.88.3.186","article-title":"Biologic therapies for juvenile arthritis","volume":"88","author":"Wilkinson","year":"2003","journal-title":"Arch Dis Child"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.10.006_bib6","first-page":"394","article-title":"Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis","volume":"30","author":"Bowyer","year":"2003","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.10.006_bib7","doi-asserted-by":"crossref","first-page":"ep29","DOI":"10.1136\/adc.2004.066050","article-title":"Juvenile idiopathic arthritis","volume":"91","author":"McCann","year":"2006","journal-title":"Arch Dis Child Educ Pract Ed"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.10.006_bib8","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s00296-007-0399-1","article-title":"Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis","volume":"28","author":"Kuemmerle-Deschner","year":"2007","journal-title":"Rheumatol Int"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib9","first-page":"15","article-title":"Biologic therapies in juvenile idiopathic arthritis: why and for whom?","volume":"32","author":"McCann","year":"2007","journal-title":"Acta Reumatol Port"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.10.006_bib10","first-page":"2147","article-title":"Bioethical issues in autologous stem cell transplantation in children and adults with arthritis","volume":"28","author":"Laxer","year":"2001","journal-title":"J Rheumatol"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.10.006_bib11","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/art.20288","article-title":"A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate","volume":"50","author":"Ruperto","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.10.006_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/acr.20460","article-title":"2011 American College of Rheumatology recommendations for the treatment of juvenile idiopathic arthritis: initiation and safety monitoring of therapeutic agents for the treatment of arthritis and systemic features","volume":"63","author":"Beukelman","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"11","key":"10.1016\/j.semarthrit.2012.10.006_bib13","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1056\/NEJM200003163421103","article-title":"Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group","volume":"342","author":"Lovell","year":"2000","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.10.006_bib14","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.2165\/00003495-200767080-00011","article-title":"Etanercept. A review of its use in the management of rheumatoid arthritis","volume":"67","author":"Dhillon","year":"2007","journal-title":"Drugs"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/PEC.0b013e31802c61ae","article-title":"Review of medications used in juvenile rheumatoid arthritis","volume":"23","author":"Guthrie","year":"2007","journal-title":"Pediatr Emergency Care"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.10.006_bib16","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1517\/13543784.17.3.349","article-title":"The future of the IL-1 receptor antagonist anakinra: from rheumatoid arthritis to adult-onset Still's disease and systemic juvenile idiopathic arthritis","volume":"17","author":"Kalliolias","year":"2008","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib17","first-page":"1989","article-title":"Les inhibiteurs du TNF-\u03b1. Les indications s'\u00e9tendent","volume":"53","author":"Fain","year":"2003","journal-title":"La Rev Pract"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib18","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1529-8019.2007.00138.x","article-title":"TNF-\u03b1 inhibitors","volume":"20","author":"Jackson","year":"2007","journal-title":"Dermatol Ther"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.10.006_bib19","first-page":"205","article-title":"Juvenile idiopathic arthritis: therapies in the 21st century","volume":"65","author":"Haines","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.10.006_bib20","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S1699-258X(08)71809-6","article-title":"Cambios entre anti-TNF, estan siempre justificados?","volume":"4","author":"Carmona","year":"2008","journal-title":"Reumatol Clin"},{"issue":"5 Suppl 1","key":"10.1016\/j.semarthrit.2012.10.006_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semarthrit.2005.01.001","article-title":"Distinct mechanisms of action of tumor necrosis factor antagonists: what are the clinical implications?","volume":"34","author":"Rigby","year":"2005","journal-title":"Semin Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.semarthrit.2012.10.006_bib22","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib23","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2007-963238","article-title":"Biologics for treatment of juvenile idiopathic arthritis\u2014update 2007","volume":"32","author":"Horneff","year":"2007","journal-title":"Akt Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.10.006_bib24","first-page":"211","article-title":"Juvenile idiopathic arthritis: an update on clinical and therapeutic approaches","volume":"20","author":"Quarta","year":"2005","journal-title":"Ann Intern Med"},{"issue":"Suppl 3","key":"10.1016\/j.semarthrit.2012.10.006_bib25","first-page":"2","article-title":"Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007","volume":"66","author":"Furst","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"1224","key":"10.1016\/j.semarthrit.2012.10.006_bib26","first-page":"U1706","article-title":"inhibitors for inflammatory arthritis in New Zealand","volume":"118","author":"Grainger","year":"2005","journal-title":"N Z Med J"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.10.006_bib27","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2165\/00002018-200225030-00004","article-title":"Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept","volume":"25","author":"Fleischmann","year":"2002","journal-title":"Drug Saf"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib28","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1093\/rheumatology\/keh620","article-title":"Outcome following onset of juvenile idiopathic inflammatory arthritis: I. Frequency of different outcomes","volume":"44","author":"Adib","year":"2005","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib29","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/acr.20337","article-title":"Cost-effectiveness of biologics in polyarticular-course juvenile idiopathic arthritis patients unresponsive to disease modifying anti-rheumatic drugs","volume":"63","author":"Ungar","year":"2011","journal-title":"Arthritis Care Res"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.10.006_bib30","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R","article-title":"Preliminary definition of improvement in juvenile arthritis","volume":"40","author":"Giannini","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.10.006_bib31","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1002\/art.22838","article-title":"A randomized, placebo-controlled trial of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis","volume":"56","author":"Ruperto","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"13","key":"10.1016\/j.semarthrit.2012.10.006_bib32","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1001\/jama.294.13.1671","article-title":"Medical treatment of juvenile idiopathic arthritis","volume":"294","author":"Hashkes","year":"2005","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib33","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.10710","article-title":"Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: interim results from an ongoing multicenter, open-label, extended-treatment trial","volume":"48","author":"Lovell","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.10.006_bib34","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJMoa0706290","article-title":"Adalimumab with or without methotrexate in juvenile rheumatoid arthritis","volume":"359","author":"Lovell","year":"2008","journal-title":"N Engl J Med"},{"issue":"9636","key":"10.1016\/j.semarthrit.2012.10.006_bib35","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0140-6736(08)60998-8","article-title":"Abatacept in children with juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled withdrawal trial","volume":"372","author":"Ruperto","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib36","unstructured":"Google Translate. Google Inc. Available at: http:\/\/translate.google.com. Accessed June 2012."},{"issue":"11","key":"10.1016\/j.semarthrit.2012.10.006_bib37","first-page":"649","article-title":"Swiss Registry for TNF-alpha blockers in children and adolescents with rheumatological diseases","volume":"99","author":"Sauvain","year":"2010","journal-title":"Schweiz Rundsch Med Prax"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.10.006_bib38","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.anpedi.2008.12.011","article-title":"Efficacy of etanercept in the treatment of juvenile idiopathic arthritis","volume":"70","author":"De Inocencio Arocena","year":"2009","journal-title":"Ann Pediatr"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib39","first-page":"50","article-title":"Long-term evaluation of infliximab in the treatment of persistently active juvenile idiopathic arthritis refractory to conventional therapy","volume":"59","author":"De Marco","year":"2007","journal-title":"Reumatismo"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib40","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Controlled Clin Trials"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib41","unstructured":"Public Health Resource Unit NHS. Cohort studies: 12 questions to help you make sense of a cohort study, http:\/\/www.sph.nhs.uk\/sph-files\/casp-appraisal-tools\/cohort%2012%20questions.pdf; 2004 [accessed April 2012]."},{"key":"10.1016\/j.semarthrit.2012.10.006_bib42","unstructured":"Oxford Centre for Evidence-based Medicine. Levels of evidence, http:\/\/www.cebm.net\/index.aspx?o=1025; 2009 [accessed April 2012]."},{"issue":"2","key":"10.1016\/j.semarthrit.2012.10.006_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s10067-008-0995-9","article-title":"Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter study","volume":"28","author":"Ilowite","year":"2009","journal-title":"Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.10.006_bib44","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/art.34343","article-title":"Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis","volume":"64","author":"Wallace","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.10.006_bib45","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1136\/ard.2010.143347","article-title":"Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial","volume":"70","author":"Tynjala","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib46","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/art.22331","article-title":"Outcomes after switching from one anti-tumor necrosis factor alfa agent to a second anti-tumor necrosis factor alfa agent in patients with rheumatoid arthritis. Results from a large UK national cohort study","volume":"56","author":"Hyrich","year":"2007","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.10.006_bib47","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1002\/art.24777","article-title":"Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis","volume":"60","author":"Giannini","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.10.006_bib48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1136\/ard.2007.087593","article-title":"Safety and efficacy of combination of Etanercept and Methotrexate compared to treatment with Etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry","volume":"68","author":"Horneff","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib49","doi-asserted-by":"crossref","unstructured":"Mori M, Takei S, Imagawa T, Imanaka H, Nerome Y, Kurosawa R, et al. Etanercept in the treatment of disease-modifying anti-rheumatic drug (DMARD)-refractory polyarticular course juvenile idiopathic arthritis: experience from Japanese clinical trials. Mod Rheumatol 2011;21(6):572-8.","DOI":"10.3109\/s10165-011-0450-7"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib50","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/rheumatology\/keq292","article-title":"Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis","volume":"50","author":"Papsdorf","year":"2011","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.semarthrit.2012.10.006_bib51","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1093\/rheumatology\/ker103","article-title":"Experiences with tumour necrosis factor-alpha inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry","volume":"50","author":"Sevcic","year":"2011","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib52","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1093\/rheumatology\/keq308","article-title":"Duration of etanercept treatment and reasons for discontinuation in a cohort of juvenile idiopathic arthritis patients","volume":"50","author":"Southwood","year":"2011","journal-title":"Rheumatology"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.10.006_bib53","doi-asserted-by":"crossref","first-page":"SR35","DOI":"10.12659\/MSM.882109","article-title":"Etanercept treatment in juvenile idiopathic arthritis: the Polish registry","volume":"17","author":"Zuber","year":"2011","journal-title":"Med Sci Monit"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.10.006_bib54","doi-asserted-by":"crossref","first-page":"665","DOI":"10.3899\/jrheum.090550","article-title":"Delayed clinical response in patients with juvenile idiopathic arthritis treated with etanercept","volume":"37","author":"Otten","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib55","doi-asserted-by":"crossref","unstructured":"Halbig M, Horneff G. Improvement of functional ability in children with juvenile idiopathic arthritis by treatment with etanercept. Rheumatol Int 2009;30(2):229-38.","DOI":"10.1007\/s00296-009-0942-3"},{"issue":"Suppl II","key":"10.1016\/j.semarthrit.2012.10.006_bib56","first-page":"268","article-title":"Safety and efficacy of once weekly etanercept 0.8mg\/kg: interim analysis of a multicentre 12 weeks open trial in active juvenile idiopathic arthritis","volume":"67","author":"Horneff","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.10.006_bib57","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1136\/ard.2007.087411","article-title":"Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register","volume":"68","author":"Prince","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2012.10.006_bib58","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1002\/art.23427","article-title":"Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis","volume":"58","author":"Lovell","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.10.006_bib59","first-page":"688","article-title":"Preliminary evidence that etanercept may reduce radiographic progression in juvenile idiopathic arthritis","volume":"26","author":"Nielsen","year":"2008","journal-title":"Clin Exp Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.10.006_bib60","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/art.21885","article-title":"Long-term safety and efficacy of etanercept in children with polyarticular-course juvenile rheumatoid arthritis","volume":"54","author":"Lovell","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.10.006_bib61","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3109\/s10165-005-0431-9","article-title":"Pharmacokinetics, efficacy, and safety of short-term (12 weeks) etanercept for methotrexate-refractory polyarticular juvenile idiopathic arthritis in Japan","volume":"15","author":"Mori","year":"2005","journal-title":"Mod Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2012.10.006_bib62","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1136\/ard.2003.014886","article-title":"The German etanercept registry for treatment of juvenile idiopathic arthritis","volume":"63","author":"Horneff","year":"2004","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.10.006_bib63","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1002\/art.10885","article-title":"Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type","volume":"48","author":"Quartier","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.10.006_bib64","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.3899\/jrheum.111555","article-title":"Safety and efficacy of etanercept in a cohort of patients with juvenile idiopathic arthritis under 4 years of age","volume":"39","author":"Bracaglia","year":"2012","journal-title":"J Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.10.006_bib65","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/ard.2009.100354","article-title":"Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension","volume":"69","author":"Ruperto","year":"2010","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.10.006_bib66","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/art.20793","article-title":"Efficacy of repeated intravenous infusions of an anti-tumor necrosis factor alpha monoclonal antibody, infliximab, in persistently active, refractory juvenile idiopathic arthritis: results of an open-label prospective study","volume":"52","author":"Gerloni","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib67","first-page":"131","article-title":"The \u2018head-to-head\u2019 comparison of etanercept and infliximab in treating children with juvenile idiopathic arthritis","volume":"29","author":"Lamot","year":"2011","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2012.10.006_bib68","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1136\/ard.2007.087130","article-title":"Drug survival of the first and second course of antitumour necrosis factor agents in juvenile idiopathic arthritis","volume":"68","author":"Tynjala","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.10.006_bib69","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"Gerloni","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2012.10.006_bib70","doi-asserted-by":"crossref","first-page":"101","DOI":"10.3109\/03009742.2010.517546","article-title":"Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis","volume":"40","author":"Trachana","year":"2011","journal-title":"Scand J Rheumatol"},{"issue":"6","key":"10.1016\/j.semarthrit.2012.10.006_bib71","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1002\/art.27431","article-title":"Long-term safety and efficacy of abatacept in children with juvenile idiopathic arthritis","volume":"62","author":"Ruperto","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.10.006_bib72","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1007\/s10067-011-1720-7","article-title":"Efficacy and safety of repeat courses of rituximab treatment in patients with severe refractory juvenile idiopathic arthritis","volume":"30","author":"Alexeeva","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2012.10.006_bib73","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1093\/rheumatology\/kep122","article-title":"Safety and efficacy of once weekly etanercept 0.8 mg\/kg in a multicentre 12 week trial in active polyarticular course juvenile idiopathic arthritis","volume":"48","author":"Horneff","year":"2009","journal-title":"Rheumatology"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib74","first-page":"2290","article-title":"Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis","volume":"31","author":"Wallace","year":"2004","journal-title":"J Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.10.006_bib75","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2217\/17460816.3.3.239","article-title":"Advances in pediatric rheumatology","volume":"3","author":"Cimaz","year":"2008","journal-title":"Future Rheumatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2012.10.006_bib76","first-page":"244","article-title":"Biological therapy with TNF-inhibitors in pediatric rheumatology. Review of the literature and personal experience","volume":"59","author":"Gerloni","year":"2007","journal-title":"Reumatismo"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib77","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/11595980-000000000-00000","article-title":"Defining juvenile idiopathic arthritis remission and optimum time for disease-modifying anti-rheumatic drug withdrawal: why we need a consensus","volume":"14","author":"Broughton","year":"2012","journal-title":"Paediatr Drugs"},{"issue":"1","key":"10.1016\/j.semarthrit.2012.10.006_bib78","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbspin.2006.07.001","article-title":"When should we use TNF antagonists in children with rheumatic disease?","volume":"74","author":"Quartier","year":"2007","journal-title":"Joint Bone Spine"},{"issue":"Suppl 65","key":"10.1016\/j.semarthrit.2012.10.006_bib79","first-page":"22","article-title":"Tides of inflammation: impact of biologics","volume":"29","author":"St. Clair","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2012.10.006_bib80","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.clim.2007.08.012","article-title":"TNF\u03b1 blockade in human diseases: an overview of efficacy and safety","volume":"126","author":"Lin","year":"2008","journal-title":"Clin Immunol"},{"issue":"9","key":"10.1016\/j.semarthrit.2012.10.006_bib81","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1358\/dot.2006.42.9.1025692","article-title":"Tocilizumab: blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders","volume":"42","author":"Paul-Pletzer","year":"2006","journal-title":"Drugs Today"},{"issue":"9617","key":"10.1016\/j.semarthrit.2012.10.006_bib82","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212002636?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017212002636?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,19]],"date-time":"2018-10-19T12:01:28Z","timestamp":1539950488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017212002636"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":82,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["S0049017212002636"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2012.10.006","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}